Recombinant Mouse CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 (St3gal1)

What are the optimal storage conditions for recombinant mouse St3gal1?

Recombinant mouse St3gal1 protein requires careful handling to maintain its enzymatic activity. The protein should be stored at -80°C immediately upon receipt, as freeze-thaw cycles significantly reduce enzymatic activity. The standard storage buffer composition is 25 mM Tris-HCl, 100 mM glycine at pH 7.3 with 10% glycerol, which helps maintain protein stability during freeze-thaw cycles . For longer-term storage projects, it is recommended to aliquot the protein in smaller volumes before freezing to minimize freeze-thaw events. The protein typically remains stable for 12 months from the date of receipt when stored under these conditions .

When preparing the protein for experimental use, thaw aliquots rapidly at 37°C followed by immediate transfer to ice to prevent activity loss. For cell culture applications, sterile filtration is essential, though researchers should account for an approximate 10-15% protein loss during filtration . Activity assessments before and after filtration can help quantify this loss and adjust experimental concentrations accordingly.

What are the considerations for using recombinant St3gal1 in glycan modification experiments?

When designing glycan modification experiments with recombinant St3gal1, several critical factors must be considered. The enzyme specifically transfers sialic acid to galactose residues of core 1 O-glycans (Galβ1-3GalNAc) to produce sialyl-T antigen (NeuAcα2-3Galβ1-3GalNAc) . This specificity means that appropriate acceptor structures must be present on target glycoproteins or synthetic substrates.

For in vitro glycan modification experiments, researchers should optimize:

• Substrate concentration: Titrate both CMP-sialic acid donor and acceptor substrates to determine optimal concentrations

• Reaction time: Kinetic analysis with time points ranging from 5-60 minutes can establish optimal reaction duration

• Buffer composition: Optimal activity requires pH 6.5-7.0 and presence of divalent cations (typically Mn²⁺ at 5-10 mM)

• Temperature: While 37°C is standard, temperature sensitivity analysis may be necessary for specific applications

When modifying cell surface glycans, pretreatment with neuraminidase may be necessary to remove existing sialic acids and expose potential St3gal1 acceptor sites. For verification of modification, analytical methods such as mass spectrometry, high-performance liquid chromatography, or lectin binding assays should be employed. Importantly, St3gal1 primarily acts on O-glycans rather than N-glycans, so experimental designs should account for this preference .

How can St3gal1 knockout or overexpression systems be established for functional studies?

Establishing stable St3gal1 knockout or overexpression systems requires careful consideration of the experimental model and research questions. For knockout systems, CRISPR/Cas9 has proven effective in targeting St3gal1, as demonstrated in TRAMP-C2 cells where complete knockout resulted in significant reduction of α2-3-sialylation . Guide RNA design should target early exons to ensure complete loss of function.

For St3gal1 overexpression systems, mammalian expression vectors with CMV promoters have been successfully employed in cell lines such as LNCaP and CWR22Rv1 . The following table summarizes key considerations for both approaches:

Verification of successful modification should include both genetic confirmation (PCR, sequencing) and functional validation (enzymatic activity, glycan profile analysis). For knockout systems, complete absence of α2-3-sialylation should be confirmed, as related sialyltransferases may partially compensate for St3gal1 loss . Assessment of phenotypic changes should include proliferation, colony formation, and 3D culture behavior, though St3gal1 modification alone may not significantly alter these parameters in vitro .

How does St3gal1 contribute to tumor immune evasion mechanisms?

St3gal1 plays a crucial role in tumor immune evasion through the generation of sialoglycan ligands that interact with inhibitory Siglec receptors on immune cells. Recent research has demonstrated that St3gal1-mediated sialylation creates binding sites for Siglec-7 and Siglec-9 receptors, which are primarily expressed on natural killer (NK) cells and myeloid cells . These interactions trigger inhibitory signaling that dampens anti-tumor immune responses.

In prostate cancer specifically, St3gal1 knockout models show dramatic failure of tumor engraftment in immunocompetent mice despite normal in vitro growth capabilities, strongly suggesting immune-mediated rejection . Flow cytometry analysis using engineered Siglec-Fc proteins has confirmed that St3gal1 knockdown significantly reduces Siglec-7 and Siglec-9 ligands on cancer cell surfaces .

The immune evasion mechanism involves:

• St3gal1 upregulation in tumor cells, particularly following androgen deprivation therapy

• Increased α2-3-sialylation of O-glycans on tumor cell surfaces

• Enhanced binding of inhibitory Siglec receptors on immune cells

• Suppression of anti-tumor immune responses, particularly NK cell and myeloid cell activity

Methodologically, researchers investigating these mechanisms should consider dual approaches of in vitro binding assays with recombinant Siglec proteins and in vivo tumor growth studies in immunocompetent versus immunodeficient models to distinguish immune-mediated from intrinsic growth effects .

What is the relationship between androgen receptor signaling and St3gal1 expression in prostate cancer?

The relationship between androgen receptor (AR) signaling and St3gal1 expression represents a critical regulatory axis in prostate cancer. Transcriptomic analysis of prostate adenocarcinoma samples has revealed a significant inverse correlation between AR signaling activity and St3gal1 expression . Multiple lines of evidence support this relationship:

• Gene set enrichment analysis (GSEA) of TCGA prostate adenocarcinoma cohort showed that the androgen response gene set was negatively enriched in tumors with high St3gal1 expression

• In vitro experiments with LNCaP cells demonstrated that treatment with R1881 (an AR ligand) significantly decreased St3gal1 protein levels compared to steroid-depleted controls

• siRNA knockdown of AR resulted in a 3-fold increase in St3gal1 mRNA levels

• Analysis of 138 castration-resistant prostate cancer (CRPC) tumors showed negative correlation between St3gal1 and AR signaling markers (KLK3, NKX3.1, TMPRSS2)

• Enzalutamide (AR inhibitor) treatment increased St3gal1 expression in both cell models and patient samples

Methodologically, researchers should examine St3gal1 expression changes following AR modulation using multiple approaches:

• Transcriptomic analysis (RNA-seq or qRT-PCR) for mRNA level changes

• Western blotting for protein level assessment

• Flow cytometry with sialic acid-binding lectins to assess functional impact on surface sialylation

• Evaluation in patient samples before and after androgen deprivation therapy

This inverse relationship has significant clinical implications, as antiandrogen therapies may inadvertently promote immune evasion through St3gal1 upregulation, potentially contributing to treatment resistance .

How can St3gal1-mediated sialylation be targeted therapeutically in cancer?

Developing therapeutic strategies targeting St3gal1-mediated sialylation represents an emerging approach in cancer immunotherapy. Several methodological approaches warrant consideration:

• Direct enzymatic inhibition: Small molecule inhibitors targeting St3gal1 catalytic activity can reduce tumor surface sialylation. Rational design strategies based on the enzyme's crystal structure or high-throughput screening of compound libraries can identify potential inhibitors. Candidate molecules should be evaluated for:

  • In vitro inhibition potency (IC50 determination)

  • Selectivity against other sialyltransferases

  • Cell permeability and stability

  • Effects on surface sialylation in living cells

• Sialidase treatment: Exogenous neuraminidases can remove sialic acids from tumor cell surfaces. Targeted delivery approaches using antibody-enzyme conjugates can improve specificity for tumor cells while minimizing off-target effects.

• Siglec-blocking antibodies: Antibodies targeting Siglec-7 and Siglec-9 can prevent interaction with their sialylated ligands, potentially restoring immune cell activity. These should be tested in co-culture systems with NK cells and tumor cells to assess functional immune reactivation.

• Combined approaches with established therapies: Given that androgen receptor inhibitors upregulate St3gal1, combination strategies that pair these standard treatments with sialylation inhibitors may prevent the development of immune evasion mechanisms .

For preclinical validation, researchers should employ immunocompetent mouse models that recapitulate the St3gal1-mediated immune suppression observed in human cancers. The significant failure of St3gal1-knockout cells to engraft in immunocompetent mice provides strong rationale for therapeutic development in this direction .

What are the technical challenges in analyzing the specific O-glycan structures modified by St3gal1?

Analyzing the specific O-glycan structures modified by St3gal1 presents several technical challenges that require sophisticated methodological approaches. St3gal1 specifically sialylates the Galβ1-3GalNAc structure (T-antigen) to form NeuAcα2-3Galβ1-3GalNAc (sialyl-T antigen) , but comprehensive characterization of these modifications requires:

• Sample preparation challenges: O-glycans must be carefully released from proteins while preserving sialic acid linkages, which are sensitive to acid hydrolysis. Beta-elimination with mild alkaline conditions (typically 50 mM NaOH with 1 M NaBH4) at 45°C for 16-24 hours provides gentle release conditions.

• Mass spectrometry analysis considerations:

  • Negative ion mode detection is preferred for sialylated glycans

  • Derivatization approaches (permethylation or ethyl esterification) can stabilize sialic acids during MS analysis

  • Fragmentation techniques (CID, HCD, ETD) must be optimized to distinguish linkage isomers

  • Multiple-stage tandem MS may be necessary to fully characterize complex structures

• Separation challenges: Closely related glycan structures require high-resolution separation techniques:

  • Porous graphitized carbon (PGC) chromatography

  • Hydrophilic interaction chromatography (HILIC)

  • Ion mobility spectrometry coupled with MS (IMS-MS)

• Reference standards: Limited availability of well-characterized O-glycan standards hampers definitive identification. Researchers may need to enzymatically synthesize standards using purified glycosyltransferases.

• Site-specific glycopeptide analysis: Determining which specific proteins and sites are modified by St3gal1 requires glycoproteomic approaches that preserve the peptide-glycan connection. This typically employs electron transfer dissociation (ETD) fragmentation to maintain the glycan-peptide bond while fragmenting the peptide backbone.

Recent technological advances combining multiple orthogonal techniques provide the most comprehensive structural information. For example, coupling IMS-MS with isomer-sensitive fragmentation and retention time matching against synthetic standards can provide high-confidence assignments of St3gal1-modified structures .

What tissue-specific expression patterns does St3gal1 exhibit and how are they regulated?

St3gal1 exhibits distinct tissue-specific expression patterns that reflect its diverse biological functions. The enzyme is widely expressed in mammalian tissues, with particularly high levels detected in placenta, liver, and skeletal muscle . Understanding these expression patterns and their regulation requires comprehensive analysis at both transcript and protein levels.

In mouse models, St3gal1 expression varies significantly across development and tissue types. Regulatory elements controlling St3gal1 expression include:

• Transcriptional regulation: The St3gal1 promoter contains binding sites for multiple transcription factors, including:

  • Sp1/Sp3 sites mediating basal transcription

  • STAT3 response elements that link inflammation to St3gal1 upregulation

  • HIF-1α binding sites that increase expression under hypoxic conditions

• Epigenetic regulation: DNA methylation and histone modifications of the St3gal1 promoter region influence expression levels. In cancer contexts, hypomethylation of specific CpG islands correlates with increased expression.

• Post-transcriptional regulation: microRNAs including miR-199a and miR-125b have been identified as negative regulators of St3gal1 expression in various cellular contexts.

• Hormonal regulation: As evidenced in prostate cancer models, St3gal1 is negatively regulated by androgen receptor signaling . This suggests broader hormonal control mechanisms may exist in other hormone-responsive tissues.

For methodological assessment of St3gal1 expression across tissues, researchers should employ complementary approaches:

• qRT-PCR for transcript quantification

• Western blotting or immunohistochemistry for protein-level assessment

• Enzyme activity assays using tissue lysates to measure functional expression

• Single-cell RNA sequencing to identify cell-type specific expression patterns within heterogeneous tissues

These analyses are particularly important when selecting appropriate animal models for St3gal1-related research, as expression patterns may differ between species, potentially affecting translational relevance .

How do genomic alterations in St3gal1 correlate with cancer progression?

Genomic alterations in St3gal1 show significant correlations with cancer progression, particularly in prostate cancer. Comprehensive analysis of genomic data reveals several key patterns that researchers should consider:

St3gal1 amplification occurs in approximately 8% of hormone-dependent prostate cancer patients and increases to approximately 20% in castration-resistant prostate cancer (CRPC) patients . This amplification pattern suggests selective pressure for increased St3gal1 expression during disease progression. Patient stratification based on St3gal1 genomic alterations shows that those with St3gal1 amplification have significantly poorer disease-free survival (p=0.007) .

Methodological approaches for investigating these correlations include:

• Genomic analysis techniques:

  • Fluorescence in situ hybridization (FISH) for direct visualization of gene amplification

  • Quantitative PCR for copy number variation analysis

  • Next-generation sequencing for comprehensive genomic profiling

  • Single nucleotide polymorphism (SNP) array analysis

• Expression correlation studies:

  • Integrate transcriptomic data with genomic alterations to assess expression-amplification relationships

  • Analyze co-expression networks to identify pathways associated with St3gal1 alterations

  • Perform multivariate analysis to control for confounding factors

• Functional validation approaches:

  • Create cell line models with St3gal1 amplification using CRISPR activation systems

  • Assess biological impact of amplification through phenotypic assays

  • Evaluate response to therapies in amplified versus non-amplified models

• Clinical correlation methodologies:

  • Retrospective analysis of patient cohorts with genomic data and outcome measures

  • Development of tissue microarrays for high-throughput analysis of St3gal1 status

  • Integration with other biomarkers for improved prognostic models

The significant correlation between St3gal1 amplification and poorer disease-free survival suggests its potential utility as a prognostic biomarker, particularly in the context of hormone therapy resistance . Researchers should consider incorporating St3gal1 genomic status assessment into clinical trial designs, especially for immunotherapy approaches that may be affected by sialylation-mediated immune evasion.